<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82257">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01830348</url>
  </required_header>
  <id_info>
    <org_study_id>DSC127-2012-01</org_study_id>
    <nct_id>NCT01830348</nct_id>
  </id_info>
  <brief_title>Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers</brief_title>
  <acronym>STRIDE 1</acronym>
  <official_title>A Randomized, Double-blind, Parallel-group, Vehicle-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DSC127 in Treating Non-healing Foot Ulcers in Subjects With Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Derma Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Integrium</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Derma Sciences, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if DSC127 is effective in increasing incidence of
      complete wound closure at 10 weeks confirmed at a visit 2 weeks later when compared to the
      vehicle (gel without active ingredient) in subjects with diabetes mellitus (DM) who have
      chronic Wagner Grade 1 or 2 plantar neuropathic foot ulcers, 0.75 - 6 cm2 in size.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will undergo a two week screening period to assess plantar ulcer healing, and those
      healing less than 30% will be eligible for randomization, providing they meet all other
      inclusion criteria.  Four weeks of blinded &quot;treatment&quot; follows the screening period, and an
      observation period of six weeks (to 10 weeks post first treatment) follows the 4-week
      treatment period.  If the ulcer closes during the treatment or observation period a visit
      two weeks later is required to confirm closure, and at this time the subject enters a
      durability assessment period of up to 12 weeks.

      All aspects of Standard of Care are followed throughout the study period
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The proportion of subjects with a target ulcer which achieves complete wound closure (skin re-epithelialization without drainage or dressing requirements) up to 10 weeks (confirmed at a study visit 2 weeks later).</measure>
    <time_frame>Target ulcer must achieve complete wound closure by 10 weeks post first treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Primary endpoint of complete closure is assessed by the Principle Investigator at the site; ulcer measurements are assessed using the Canfield system and photographs are collected as confirmation of closure via the Canfield system.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to the visit where the target ulcer achieves confirmed complete wound closure occurs</measure>
    <time_frame>Weekly assessments to ten weeks post first treatment dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Percent reduction in ulcer area per week (closure rate)</measure>
    <time_frame>Weekly ulcer tracings to calculate area of ulcer, measurements continue to ten weeks post first treatment dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Calculated weekly for up to ten weeks</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of target ulcer recurrence, time to ulcer recurrence, and number of days target ulcer remains closed after confirmed complete wound closure has been established.</measure>
    <time_frame>Assessed during a 12 week durability period following the confirmation of complete wound closure</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">422</enrollment>
  <condition>Diabetic Foot Ulcers</condition>
  <arm_group>
    <arm_group_label>DSC127</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DSC127 0.03% in a vehicle gel (hydroxyethyl cellulose (HEC) with parabens)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle gel comprising HEC with parabens</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DSC127</intervention_name>
    <description>DSC127 0.03%, daily topical application to diabetic foot ulcer for a period of up to 28 days or until ulcer closure, whichever is sooner</description>
    <arm_group_label>DSC127</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo vehicle gel</intervention_name>
    <arm_group_label>Vehicle gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female ambulatory subject age ≥18 years at the time of informed consent who
             has the ability and willingness to understand and comply with study procedures and to
             give written informed consent prior to enrollment in the study or initiation of study
             procedures

          2. Has type 1 or type 2 DM under metabolic control as confirmed by a glycosylated
             hemoglobin (HbA1c) of ≤12% and a serum creatinine level of ≤3mg/dL

          3. At Screening and at Baseline (prior to randomization), subject has at least one ulcer
             that fulfills all of the following criteria:

               -  Present for ≥1 month and ≤1 year

               -  Partial- or full- thickness and not involving bone, tendon, or capsule (probing
                  to tendon or capsule)

               -  Has no sign of infection or osteomyelitis

               -  Plantar neuropathic ulcer; ulcer must be predominantly on the plantar surface to
                  ensure adequate off-loading

               -  Size of the target ulcer must be 0.75 - 6 cm2

               -  Target ulcer must be non-healing as defined as &lt;30% reduction in size in
                  response to standard of care during the Screening Period

          4. Has an ankle brachial index (ABI) &gt;0.7 on the leg of the foot with the target ulcer

          5. Has an assessment of the baseline level of neuropathy of the foot using
             Semmes-Weinstein filaments.

          6. A female subject of childbearing potential must have a negative serum pregnancy test
             at the time of Screening, and must be willing to use a medically acceptable method of
             birth control, such as Essure®, hormonal contraception (oral pills, implantable
             device, or skin patch), intrauterine device, tubal ligation, or double barrier
             throughout the study.  A female subject of childbearing potential who practices
             abstinence is not required to employ birth control.

        Exclusion Criteria:

          1. Has a known hypersensitivity to any of the investigational drug or vehicle components

          2. Has been exposed to any investigational agent within 30 days of entry into the study

          3. A female who is pregnant or nursing

          4. Has active malignant disease of any kind. A subject, who has had a malignant disease
             in the past, was treated and is currently disease-free, may be considered for study
             entry.

          5. Has a history of additional risk factors for Torsade de Pointes (TdP) (e.g., heart
             failure, hypokalemia, family history of Long QT Syndrome)

          6. Has a hemoglobin of less than 10 gm/dL.

          7. Has chronic liver dysfunction evidenced by transaminase levels greater than 2 ×
             normal

          8. Is receiving hemodialysis or chronic ambulatory peritoneal dialysis (CAPD) therapy

          9. Has had prior radiation therapy of any part of the foot with the target ulcer under
             study

         10. Current use of corticosteroids and immunosuppressants (within past 8 weeks)

         11. Has an ulcer  primarily ischemic in etiology

         12. Has sickle-cell anemia, Reynaud's, or other peripheral vascular disease

         13. Has received a biologic agent to include growth factors and skin equivalents
             (Regranex®, Apligraft, or Dermagraft), in the past 30 days

         14. Has a target ulcer which is determined to be clinically infected or requires topical
             antimicrobials or agents known to affect wound healing

         15. Has a Wagner Grade 3 or greater DFU, deep abscess, or gangrene

         16. Has a baseline blood pressure (BP) reading &gt;160 systolic and/or &gt;90 diastolic mmHg.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gere S diZerega, MD</last_name>
    <role>Study Director</role>
    <affiliation>Derma Sciences, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shelagh Verco, PhD</last_name>
    <phone>805-704-1179</phone>
    <email>sverco@dermasciences.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>WILMAX Clinical Research Inc</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36680</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Candace Jenkins</last_name>
      <phone>251-340-6970</phone>
      <email>candace@wilmax.com</email>
    </contact>
    <contact_backup>
      <last_name>Dale Brown</last_name>
      <phone>251-340-6970</phone>
    </contact_backup>
    <investigator>
      <last_name>William Higgs, MD, FACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Arizona VA Healthcare System</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phyllis Houston</last_name>
      <phone>520-629-1824</phone>
      <phone_ext>6525</phone_ext>
      <email>phyllis.houston@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Robert Huey</last_name>
      <phone>520.629.1824</phone>
      <phone_ext>6525</phone_ext>
      <email>Robert.Huey@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Jodi Walters, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NEA Baptist Clinic</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Jenkins, LPN</last_name>
      <phone>870-219-9865</phone>
      <email>david.jenkins@neabaptistclinic.com</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Graf</last_name>
      <phone>870-219-9865</phone>
      <email>Brenda.graf@neabaptistclinic.com</email>
    </contact_backup>
    <investigator>
      <last_name>James Fletcher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roy O Kroeker, DPM, Inc</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Kroeker</last_name>
      <phone>559-436-8162</phone>
      <email>mem-k@pacbell.net</email>
    </contact>
    <investigator>
      <last_name>Roy Kroeker, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Long Beach Center for Clinical Research</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90807</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Tran</last_name>
      <phone>562-595-9366</phone>
      <email>a.tran@lbccr.com</email>
    </contact>
    <investigator>
      <last_name>Deanna Cheung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Foot and Ankle Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suni Allen</last_name>
      <phone>213-365-0793</phone>
      <email>sunigmka@aol.com</email>
    </contact>
    <investigator>
      <last_name>Felix Sigal, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center - Olive View</name>
      <address>
        <city>Sylmar</city>
        <state>California</state>
        <zip>91342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Farley</last_name>
      <phone>818-364-3796</phone>
      <email>mefarley@dhs.lacounty.gov</email>
    </contact>
    <contact_backup>
      <last_name>Wendy Arriaga</last_name>
      <email>warriaga@dhs.lacounty.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Peter Balingit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown Universtiy Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Benkert</last_name>
      <phone>202-444-0921</phone>
      <email>Elizabeth.A.Benkert@gunet.georgetown.edu</email>
    </contact>
    <contact_backup>
      <last_name>Zinnia Rocha</last_name>
      <phone>202-444-4121</phone>
      <email>Zinnia.M.Rocha@gunet.georgetown.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John Steinberg, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barry University Clinical Research</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Swartz, RN</last_name>
      <phone>305-836-7550</phone>
      <email>mswartz@mail.barry.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Snyder, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Wound Management Clinic</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farrah Parker</last_name>
      <phone>706-364-2966</phone>
      <email>farrah.parker@jmsburncenters.com</email>
    </contact>
    <investigator>
      <last_name>S M Abu Zaheed Hassan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr Osh and Associates Foot &amp; Leg Clinic</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>APSMO Study Coordinator</last_name>
      <phone>678-852-1355</phone>
      <email>apsmo.crc.osh.footleg@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Evaristus Oshiokpekhai, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riverdale Foot, Ankle, and Leg Clinic / APSMO</name>
      <address>
        <city>Riverdale</city>
        <state>Georgia</state>
        <zip>30274</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>APSMO Study Coordinator</last_name>
      <phone>866-218-0717</phone>
    </contact>
    <investigator>
      <last_name>Terry Dickerson, DPM, FACFAS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Joseph's/Candler Health System</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wanda Kay North</last_name>
      <phone>912-819-6194</phone>
      <email>northw@sjchs.org</email>
    </contact>
    <investigator>
      <last_name>Joseph DeHaven, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Medical Group</name>
      <address>
        <city>Granger</city>
        <state>Indiana</state>
        <zip>46530</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Emmons</last_name>
      <phone>574-647-7883</phone>
      <email>KEmmons@beaconhealthsystem.org</email>
    </contact>
    <contact_backup>
      <last_name>Leanne Chandler</last_name>
      <phone>574-647-7883</phone>
      <email>lchandler@beaconhealthsystem.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jason Grove, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston University Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myriam Costagne</last_name>
      <phone>617-414-6836</phone>
      <email>Myriam.Costagne@bmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Victoria Lattanzi</last_name>
      <phone>617.414.6836</phone>
      <email>vlattanz@bu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Hau Pham, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jefferson City Medical Group</name>
      <address>
        <city>Jefferson City</city>
        <state>Missouri</state>
        <zip>65109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorothy Webb, RN</last_name>
      <phone>573-556-7785</phone>
      <phone_ext>2</phone_ext>
      <email>dwebb@jcmg.org</email>
    </contact>
    <investigator>
      <last_name>Jody Peter McAleer, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CarePoint Health Research Institute/ Hoboken University Medical Center</name>
      <address>
        <city>Hoboken</city>
        <state>New Jersey</state>
        <zip>07030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mercedes Martillo</last_name>
      <phone>201-795-8120</phone>
      <email>mmartillo@christhospital.org</email>
    </contact>
    <investigator>
      <last_name>John DelMonte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Carolina Foot and Ankle Specialists</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christy Lennon</last_name>
      <phone>252-830-1000</phone>
      <email>christylennon@embarqmail.com</email>
    </contact>
    <investigator>
      <last_name>Christopher Gauland, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brettany Holt</last_name>
      <phone>910-815-6108</phone>
      <email>bholt@pmg-research.com</email>
    </contact>
    <investigator>
      <last_name>Matthew Dzurik, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wound Institute and Research Center</name>
      <address>
        <city>Dunmore</city>
        <state>Pennsylvania</state>
        <zip>18512</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nanci Dobson, RN</last_name>
      <phone>570-961-8000</phone>
      <email>ndobsonrn@managewounds.com</email>
    </contact>
    <investigator>
      <last_name>Michael Moore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina Musculoskeletel Institute</name>
      <address>
        <city>Aiken</city>
        <state>South Carolina</state>
        <zip>29801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Sonderegger</last_name>
      <phone>803-226-0527</phone>
    </contact>
    <investigator>
      <last_name>Mackie Walker, Jr, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Richard C Galperin, DPM</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Davila</last_name>
      <phone>214-330-9299</phone>
      <email>vanessa@drgalperin.com</email>
    </contact>
    <investigator>
      <last_name>Richard Galperin, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fort Worth Diagnostic Clinic</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Bolling</last_name>
      <phone>817-992-2372</phone>
      <email>debo322@me.com</email>
    </contact>
    <contact_backup>
      <last_name>Marcy Conner</last_name>
      <phone>817-992-2372</phone>
      <email>marcysconner@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Byron Conner, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aspen Clinical Research</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84058</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GiGi Siddoway</last_name>
      <phone>801-342-5409</phone>
      <email>GiGiS@aspenclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Jared Clegg, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Professional Education and Research Institute</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morgan Stepanek</last_name>
      <phone>540-797-2726</phone>
      <email>mstepanek@periedu.com</email>
    </contact>
    <contact_backup>
      <last_name>Deborah Morrison, RN</last_name>
      <phone>540.797.2726</phone>
      <email>dmorrison@periedu.com</email>
    </contact_backup>
    <investigator>
      <last_name>Charles Zelen, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wenatchee Valley Medical Center Clinical Research</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Gault</last_name>
      <phone>509-665-5800</phone>
      <email>jgault@wvmedical.com</email>
    </contact>
    <investigator>
      <last_name>Brandon Child, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>March 28, 2014</lastchanged_date>
  <firstreceived_date>March 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetic foot ulcers</keyword>
  <keyword>Wagner Grade 1 or 2 foot ulcers</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
